Lizaveta A. Aboishava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lizaveta A. Aboishava has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina E. Bibik
Endocrinology Research Centre
5 shared publications - Nataliya G. Mokrysheva
Endocrinology Research Centre, 117292 Moscow, Russia
4 shared publications - Анна Константиновна Еремкина
Endocrinology Research Centre
4 shared publications - Anna M. Gorbacheva
Endocrinology Research Centre
3 shared publications - Alina R. Elfimova
Endocrinology Research Centre
2 shared publications - Ekaterina Aleksandrovna Pigarova
Endocrinology Research Centre
2 shared publications
Latest Publications
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy Ginekologii, Akušerstva i Perinatologii
- Vol. 24 (1)
Adrenogenital syndrome. Differentiated approach to treatment selection
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder leading to impaired corticosteroid synthesis due to the deficiency of one of the steroidogenic enzymes. The most common mutation in the CYP21A gene is 21-hydroxylase deficiency. Insufficient activity of this enzyme results in excessive synthesis of androgens. The main problem is the selection of glucocorticoid replacement therapy to maintain eucorticism and suppression of adrenocorticotropic hormone (ACTH) levels to eliminate hyperandrogenism. However, it is not always possible to select an adequate dose of glucocorticoids, leaving the patient in either a state of hyperandrogenism or iatrogenic Cushing’s syndrome. In women, hyperandrogenism often leads to amenorrhea and anovulatory infertility. In severe cases, when no effect can be achieved with conservative treatment in adult patients, bilateral adrenalectomy is considered. Like any surgical intervention, in addition to certain advantages, it entails a high risk of acute adrenal insufficiency, hypoglycemic states, and late complications in the form of testicular tumors and ACTH-secreting pituitary adenomas. This article presents a description of two clinical cases of patients with virilizing and salt-wasting forms of CAH. The aim of these cases was to draw the attention of practitioners to the necessity of individual assessment of potential benefits and harms of bilateral adrenalectomy, as well as to emphasize the feasibility of adrenalectomy in benign nodular adrenal hyperplasia. Key words: congenital adrenal hyperplasia, salt-wasting form, virilizing form, 21-hydroxylase deficiency, bilateral adrenalectomy, clinical case
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy Ginekologii, Akušerstva i Perinatologii
- Vol. 24 (1)
Adrenogenital syndrome. Differentiated approach to treatment selection
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder leading to impaired corticosteroid synthesis due to the deficiency of one of the steroidogenic enzymes. The most common mutation in the CYP21A gene is 21-hydroxylase deficiency. Insufficient activity of this enzyme results in excessive synthesis of androgens. The main problem is the selection of glucocorticoid replacement therapy to maintain eucorticism and suppression of adrenocorticotropic hormone (ACTH) levels to eliminate hyperandrogenism. However, it is not always possible to select an adequate dose of glucocorticoids, leaving the patient in either a state of hyperandrogenism or iatrogenic Cushing’s syndrome. In women, hyperandrogenism often leads to amenorrhea and anovulatory infertility. In severe cases, when no effect can be achieved with conservative treatment in adult patients, bilateral adrenalectomy is considered. Like any surgical intervention, in addition to certain advantages, it entails a high risk of acute adrenal insufficiency, hypoglycemic states, and late complications in the form of testicular tumors and ACTH-secreting pituitary adenomas. This article presents a description of two clinical cases of patients with virilizing and salt-wasting forms of CAH. The aim of these cases was to draw the attention of practitioners to the necessity of individual assessment of potential benefits and harms of bilateral adrenalectomy, as well as to emphasize the feasibility of adrenalectomy in benign nodular adrenal hyperplasia. Key words: congenital adrenal hyperplasia, salt-wasting form, virilizing form, 21-hydroxylase deficiency, bilateral adrenalectomy, clinical case
- Open Access
- 1 April 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (1) , 20-26
Management of primary hyperparathyroidism with rare localization of ectopic adenoma parathyroid gland
Topical diagnosis can be severely complicated in patients with primary hyperparathyroidism (PHPT) due to the ectopic placement of parathyroid gland (PTG) formations. We report a clinical case of PHPT in an 84-year-old patient caused by ectopic PTG adenoma located behind the right internal jugular vein at the level of the right submandibular gland. The impossibility of surgery for a long time due to the absence of a topical diagnosis has necessitated conservative treatment was required to get the hypercalcemia under control. In view of the concomitant deficiency of vitamin D, an attempt was made to use therapy with saturating doses of cholecalciferol under dynamic monitoring of the indicators of phosphorus-calcium metabolism, which allowed to achieve a significant decrease in PTH levels while maintaining normocalcemia.
- 1 April 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (1) , 20-26
Open AccessManagement of primary hyperparathyroidism with rare localization of ectopic adenoma parathyroid gland
Topical diagnosis can be severely complicated in patients with primary hyperparathyroidism (PHPT) due to the ectopic placement of parathyroid gland (PTG) formations. We report a clinical case of PHPT in an 84-year-old patient caused by ectopic PTG adenoma located behind the right internal jugular vein at the level of the right submandibular gland. The impossibility of surgery for a long time due to the absence of a topical diagnosis has necessitated conservative treatment was required to get the hypercalcemia under control. In view of the concomitant deficiency of vitamin D, an attempt was made to use therapy with saturating doses of cholecalciferol under dynamic monitoring of the indicators of phosphorus-calcium metabolism, which allowed to achieve a significant decrease in PTH levels while maintaining normocalcemia.
- Open Access
- 10 November 2023
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 69 (5) , 4-15
Predicting the presence of MEN1 gene mutation based on the clinical phenotype of patients with primary hyperparathyroidism
BACKGROUND: Timely referral of patients for genetic testing to rule out MEN1-associated primary PHPT is important factor in determining treatment strategy and prognosis. In the context of the limited availability of genetic testing, the search for clinical markers indicative of MEN1 gene mutations remains an extremely relevant task.AIM: To determine the diagnostic value of clinical features of primary PHPT in young patients for predicting the presence of MEN1 gene mutations.MATERIALS AND METHODS: A single-center, prospective study was conducted at the Endocrinology Research Centre, involving 273 patients with PHPT in the period 2015–2022. Based on the results of genetic and laboratory tests, patients were divided into three groups: those with MEN1 gene mutations (MEN+ group, n=71), those without MEN1 gene mutations — isolated sporadic PHPT (MEN- group, n=158), and patients with PHPT and associated endocrine gland disorders — MEN-1 syndrome phenocopies (PHEN group, n=32). Subgroups of patients younger than 40 years of age were also identified. Comparative analysis was performed among the independent groups and subgroups, and logistic regression analysis was used to develop a mathematical model for predicting the probability of the presence of MEN1 gene mutation.RESULTS: Patients in the MEN+ and MEN- groups were comparable by gender and age at manifestation, as well as calcium-phosphorus metabolism parameters and PHPT complications. In the PHEN group, PHPT manifested at older age compared to the other groups (pMEN1 gene mutation included eight predictors, with a diagnostic sensitivity of 96% and specificity of 98%.CONCLUSION: Based on the analysis performed, eight hereditary predictors of PHPT within the MEN-1 syndrome were identified. A mathematical model was developed to predict the presence of the MEN1 gene mutation in patients, which demonstrated high classification performance on the training dataset. Further refinement of the model will help improve the quality of medical care for patients with PHPT.
- 10 November 2023
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 69 (5) , 4-15
Open AccessPredicting the presence of MEN1 gene mutation based on the clinical phenotype of patients with primary hyperparathyroidism
BACKGROUND: Timely referral of patients for genetic testing to rule out MEN1-associated primary PHPT is important factor in determining treatment strategy and prognosis. In the context of the limited availability of genetic testing, the search for clinical markers indicative of MEN1 gene mutations remains an extremely relevant task.AIM: To determine the diagnostic value of clinical features of primary PHPT in young patients for predicting the presence of MEN1 gene mutations.MATERIALS AND METHODS: A single-center, prospective study was conducted at the Endocrinology Research Centre, involving 273 patients with PHPT in the period 2015–2022. Based on the results of genetic and laboratory tests, patients were divided into three groups: those with MEN1 gene mutations (MEN+ group, n=71), those without MEN1 gene mutations — isolated sporadic PHPT (MEN- group, n=158), and patients with PHPT and associated endocrine gland disorders — MEN-1 syndrome phenocopies (PHEN group, n=32). Subgroups of patients younger than 40 years of age were also identified. Comparative analysis was performed among the independent groups and subgroups, and logistic regression analysis was used to develop a mathematical model for predicting the probability of the presence of MEN1 gene mutation.RESULTS: Patients in the MEN+ and MEN- groups were comparable by gender and age at manifestation, as well as calcium-phosphorus metabolism parameters and PHPT complications. In the PHEN group, PHPT manifested at older age compared to the other groups (pMEN1 gene mutation included eight predictors, with a diagnostic sensitivity of 96% and specificity of 98%.CONCLUSION: Based on the analysis performed, eight hereditary predictors of PHPT within the MEN-1 syndrome were identified. A mathematical model was developed to predict the presence of the MEN1 gene mutation in patients, which demonstrated high classification performance on the training dataset. Further refinement of the model will help improve the quality of medical care for patients with PHPT.
- Open Access
- 13 September 2023
- Published by Endocrinology Research Centre in Endocrine Surgery
- Vol. 17 (3) , 61-70
Non-classical manifestation of multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 1 (MEN-1) is the orphan disease caused by the metachronous tumors of endocrine and non–endocrine organs. The first most frequent feature of the syndrome is primary hyperparathyroidism, however, manifestation from other components is also possible. Different medical specialists should know about this pathology because its clinical course is often varied.This clinical case of non-classical manifestation of MEN-1 demonstrates the difficulties of diagnostics, comprehensive examination and treatment of the main components of the syndrome. Timely laboratory, instrumental and genetic diagnostics plays an important role in the prevention of complications, improving the quality of life and prognosis of patients.
- 13 September 2023
- Published by Endocrinology Research Centre in Endocrine Surgery
- Vol. 17 (3) , 61-70
Open AccessNon-classical manifestation of multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 1 (MEN-1) is the orphan disease caused by the metachronous tumors of endocrine and non–endocrine organs. The first most frequent feature of the syndrome is primary hyperparathyroidism, however, manifestation from other components is also possible. Different medical specialists should know about this pathology because its clinical course is often varied.This clinical case of non-classical manifestation of MEN-1 demonstrates the difficulties of diagnostics, comprehensive examination and treatment of the main components of the syndrome. Timely laboratory, instrumental and genetic diagnostics plays an important role in the prevention of complications, improving the quality of life and prognosis of patients.
- Open Access
- 5 August 2022
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 68 (4) , 52-58
The short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment
BACKGROUND: Differential diagnosis between the normocalcemic primary hyperparathyroidism (nPHPT) and secondary hyperparathyroidism (SHPT) due to hypercalciuria remains a challenge.AIM: The aim of this study was to investigate the capability of short test with hydrochlorothiazide for the differential diagnosis of nPHPT and SHPT.MATERIALS AND METHODS: A retrospective study was conducted with the participation of 28 patients who underwent a functional test with thiazide diuretics during hospitalization in the Department of parathyroid glands pathology and mineral disorders of the Endocrinology Research Centre, Russia. Parameters of mineral metabolism were evaluated before and 3–5 days after taking hydrochlorothiazide 50 mg/day.RESULTS: According to baseline and dynamic biochemical evaluation patients were divided into 3 groups. Group 1 (n=21) included patients with confirmed PHPT, who reached hypercalcemia accompanying with an elevated level of iPTH (n=19) or an increased level of iPTH accompanying with normocalcemia (n=2). In group 1, baseline Caadj. was 2.48 mmol/l [2.47; 2.52], iPTH 107.5 pg/ml [86.8; 133.0], after short test — 2.63 mmol/l [2.59; 2.66] and 102.1 pg/ml [95,7; 124,1]. Group 2 included only one who was diagnosed with SHPT, a normal value of iPTH with concomitant normocalcemia was achieved after 4 days of hydrochlorothiazide therapy (baseline Caadj. 2.35 mmol/l, iPTH 74.5 pg/ml vs at 2.27 mmol/l and 50.7 pg/ml respectively). Patients with doubtful results of the test entered in group 3 (n=6), they did not achieve significant changes in the calcium and iPTH levels, so it was recommended to continue the test on an outpatient basis (baseline Caadj. 2.39 mmol/l [2.33;2.45], iPTH 97.0 pg/ml [83.1;117.0]); after short test — 2.47 mmol/l [2.42; 2.48] and 91.3 pg/ml [86.9; 124.0] respectively). Groups with PHPT and SHPT and doubtful results significantly differed from each other in Caadj (р=0.003, U-test, Bonferroni correction Р0=0.006), but not in iPTH, daily calciuria, eGFR, and phosphorus. There were no significant differences in the incidence of classical complications of PHPT.CONCLUSION: The diagnosis of PHPT was confirmed in 21/28 patients 3–5 days after taking hydrochlorothiazide 50 mg/day. The obtained results are significant for the differential diagnosis in hospitalized patients with an unspecified genesis of hyperparathyroidism.
- 5 August 2022
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 68 (4) , 52-58
Open AccessThe short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment
BACKGROUND: Differential diagnosis between the normocalcemic primary hyperparathyroidism (nPHPT) and secondary hyperparathyroidism (SHPT) due to hypercalciuria remains a challenge.AIM: The aim of this study was to investigate the capability of short test with hydrochlorothiazide for the differential diagnosis of nPHPT and SHPT.MATERIALS AND METHODS: A retrospective study was conducted with the participation of 28 patients who underwent a functional test with thiazide diuretics during hospitalization in the Department of parathyroid glands pathology and mineral disorders of the Endocrinology Research Centre, Russia. Parameters of mineral metabolism were evaluated before and 3–5 days after taking hydrochlorothiazide 50 mg/day.RESULTS: According to baseline and dynamic biochemical evaluation patients were divided into 3 groups. Group 1 (n=21) included patients with confirmed PHPT, who reached hypercalcemia accompanying with an elevated level of iPTH (n=19) or an increased level of iPTH accompanying with normocalcemia (n=2). In group 1, baseline Caadj. was 2.48 mmol/l [2.47; 2.52], iPTH 107.5 pg/ml [86.8; 133.0], after short test — 2.63 mmol/l [2.59; 2.66] and 102.1 pg/ml [95,7; 124,1]. Group 2 included only one who was diagnosed with SHPT, a normal value of iPTH with concomitant normocalcemia was achieved after 4 days of hydrochlorothiazide therapy (baseline Caadj. 2.35 mmol/l, iPTH 74.5 pg/ml vs at 2.27 mmol/l and 50.7 pg/ml respectively). Patients with doubtful results of the test entered in group 3 (n=6), they did not achieve significant changes in the calcium and iPTH levels, so it was recommended to continue the test on an outpatient basis (baseline Caadj. 2.39 mmol/l [2.33;2.45], iPTH 97.0 pg/ml [83.1;117.0]); after short test — 2.47 mmol/l [2.42; 2.48] and 91.3 pg/ml [86.9; 124.0] respectively). Groups with PHPT and SHPT and doubtful results significantly differed from each other in Caadj (р=0.003, U-test, Bonferroni correction Р0=0.006), but not in iPTH, daily calciuria, eGFR, and phosphorus. There were no significant differences in the incidence of classical complications of PHPT.CONCLUSION: The diagnosis of PHPT was confirmed in 21/28 patients 3–5 days after taking hydrochlorothiazide 50 mg/day. The obtained results are significant for the differential diagnosis in hospitalized patients with an unspecified genesis of hyperparathyroidism.
- Open Access
- 15 October 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (10) , 1227-1233
Mineral metabolism and COVID-19: is there a connection?
Due to global spread of COVID-19, the search for new factors that could influence its clinical course becomes highly important. This review summarize the relevant publications on the association between immune system and the main regulators of mineral homeostasis including. In addition, we have highlighted the various aspects of phosphorus-calcium metabolism related to the acute respiratory diseases and in particular to COVID-19. The data about the calcium-phosphorus metabolism in SARS-CoV-2 infection is required to understand the possible clinical implications and to develop new therapeutic and preventive interventions.
- 15 October 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (10) , 1227-1233
Open AccessMineral metabolism and COVID-19: is there a connection?
Due to global spread of COVID-19, the search for new factors that could influence its clinical course becomes highly important. This review summarize the relevant publications on the association between immune system and the main regulators of mineral homeostasis including. In addition, we have highlighted the various aspects of phosphorus-calcium metabolism related to the acute respiratory diseases and in particular to COVID-19. The data about the calcium-phosphorus metabolism in SARS-CoV-2 infection is required to understand the possible clinical implications and to develop new therapeutic and preventive interventions.
- 6 December 2020
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 17 (3) , 233-240
Difficulties in diagnosis of adenomas with mixed prolactin and growth hormone secretion: case presentation
Hyperpolactinemia is a persistent excess of prolactin in the blood serum. The symptom complex of hyperprolactinemia primarily consists of disturbances in function of the reproductive system. The secretion of prolactin is under complex neuroendocrine control, which involves factors of different nature: neurotransmitters, hormones of the peripheral endocrine glands. In most cases, prolactin is secreted by pituitary cells - lactotrophs, but in some cases, hypersecretion of prolactin is combined with an excess production of growth hormone, which is typical for tumors originating from the line of progenitor cells of lactotrophs and somatotrophs of the pituitary gland, mammosomatotrophs. In this case, the symptom complex of hyperprolactinemia is accompanied by clinical manifestations of acromegaly. In patients with acromegaly, the cause of hyperprolactinemia may be pituitary stalk compression or mixed secretion of prolactin and growth hormone. Differentiation of lactotropic and somatotropic pituitary cells is determined by transcription factor Pit-1. These cell lineages are closely connected, and this may be one of the reasons for formation of tumors with mixed secretion. Reports of late presentation of acromegaly in patients previously diagnosed with prolactinomas have also been described in literature.Clinical manifestations of hyperprolactinemia can cause the patient to seek doctor’s attention before acromegalic changes in appearance develop. Careful attention is needed both to the primary diagnosis and to the clinical course of the disease in patients with hyperprolactinemia and pituitary adenoma: full assessment of hormonal status with mandatory evaluation of IGF-1 is crucial at initial examination, during further observation it may be advised to consider periodic evaluation of IGF-1 in addition to assessment of prolactin and the size of adenoma. Pituitary adenomas with mixed secretion may have a poorer prognosis.
- 6 December 2020
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 17 (3) , 233-240
Difficulties in diagnosis of adenomas with mixed prolactin and growth hormone secretion: case presentation
Hyperpolactinemia is a persistent excess of prolactin in the blood serum. The symptom complex of hyperprolactinemia primarily consists of disturbances in function of the reproductive system. The secretion of prolactin is under complex neuroendocrine control, which involves factors of different nature: neurotransmitters, hormones of the peripheral endocrine glands. In most cases, prolactin is secreted by pituitary cells - lactotrophs, but in some cases, hypersecretion of prolactin is combined with an excess production of growth hormone, which is typical for tumors originating from the line of progenitor cells of lactotrophs and somatotrophs of the pituitary gland, mammosomatotrophs. In this case, the symptom complex of hyperprolactinemia is accompanied by clinical manifestations of acromegaly. In patients with acromegaly, the cause of hyperprolactinemia may be pituitary stalk compression or mixed secretion of prolactin and growth hormone. Differentiation of lactotropic and somatotropic pituitary cells is determined by transcription factor Pit-1. These cell lineages are closely connected, and this may be one of the reasons for formation of tumors with mixed secretion. Reports of late presentation of acromegaly in patients previously diagnosed with prolactinomas have also been described in literature.Clinical manifestations of hyperprolactinemia can cause the patient to seek doctor’s attention before acromegalic changes in appearance develop. Careful attention is needed both to the primary diagnosis and to the clinical course of the disease in patients with hyperprolactinemia and pituitary adenoma: full assessment of hormonal status with mandatory evaluation of IGF-1 is crucial at initial examination, during further observation it may be advised to consider periodic evaluation of IGF-1 in addition to assessment of prolactin and the size of adenoma. Pituitary adenomas with mixed secretion may have a poorer prognosis.
- 1 January 2020
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 23 (6)
Management of pancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia type 1. Clinical case and literature review
Основными компонентами синдрома множественных эндокринных неоплазий 1-го типа (МЭН-1) являются опухоли околощитовидных желез, передней доли гипофиза и панкреатические нейроэндокринные неоплазии (Пан-НЭН). Именно Пан-НЭН на сегодняшний день представляются одним из ключевых факторов, лимитирующих продолжительность жизни пациентов с синдромом МЭН-1, что обусловливает актуальность их своевременной диагностики и эффективного лечения. Тактика ведения пациентов, особенно больных с диссеминированной формой заболевания, бывает неоднозначной, а возможности — ограниченными. В статье представлен клинический случай пациентки с синдромом МЭН-1 и прогрессирующими Пан-НЭН; обсуждаются уже принятые в клинической практике методы лечения, а также перспективные направления в этой области.
- 1 January 2020
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 23 (6)
Management of pancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia type 1. Clinical case and literature review
Основными компонентами синдрома множественных эндокринных неоплазий 1-го типа (МЭН-1) являются опухоли околощитовидных желез, передней доли гипофиза и панкреатические нейроэндокринные неоплазии (Пан-НЭН). Именно Пан-НЭН на сегодняшний день представляются одним из ключевых факторов, лимитирующих продолжительность жизни пациентов с синдромом МЭН-1, что обусловливает актуальность их своевременной диагностики и эффективного лечения. Тактика ведения пациентов, особенно больных с диссеминированной формой заболевания, бывает неоднозначной, а возможности — ограниченными. В статье представлен клинический случай пациентки с синдромом МЭН-1 и прогрессирующими Пан-НЭН; обсуждаются уже принятые в клинической практике методы лечения, а также перспективные направления в этой области.